Show simple item record

dc.contributor.authorByrne, William L
dc.contributor.authorMills, Kingston H G
dc.contributor.authorLederer, James A
dc.contributor.authorO'Sullivan, Gerald C
dc.date.accessioned2012-01-31T16:38:08Z
dc.date.available2012-01-31T16:38:08Z
dc.date.issued2012-01-31T16:38:08Z
dc.identifier.citationCancer Res. 2011 Nov 15;71(22):6915-20. Epub 2011 Nov 8.en_GB
dc.identifier.issn1538-7445 (Electronic)en_GB
dc.identifier.issn0008-5472 (Linking)en_GB
dc.identifier.pmid22068034en_GB
dc.identifier.doi10.1158/0008-5472.CAN-11-1156en_GB
dc.identifier.urihttp://hdl.handle.net/10147/206383
dc.description.abstractInfiltration of tumors by regulatory T cells confers growth and metastatic advantages by inhibiting antitumor immunity and by production of receptor activator of NF-kappaB (RANK) ligand, which may directly stimulate metastatic propagation of RANK-expressing cancer cells. Modulation of regulatory T cells can enhance the efficacy of cancer immunotherapy. Strategies include depletion, interference with function, inhibition of tumoral migration, and exploitation of T-cell plasticity. Problems with these strategies include a lack of specificity, resulting in depletion of antitumor effector T cells or global interruption of regulatory T cells, which may predispose to autoimmune diseases. Emerging technologies, such as RNA interference and tetramer-based targeting, may have the potential to improve selectivity and efficacy.
dc.language.isoengen_GB
dc.subject.meshCTLA-4 Antigen/antagonists & inhibitorsen_GB
dc.subject.meshForkhead Transcription Factors/antagonists & inhibitorsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshLymphocyte Depletionen_GB
dc.subject.meshNeoplasms/*immunology/*therapyen_GB
dc.subject.meshT-Lymphocytes, Regulatory/*immunologyen_GB
dc.titleTargeting regulatory T cells in cancer.en_GB
dc.contributor.departmentCork Cancer Research Centre, Mercy University Hospital and Leslie C. Quick Jnr., Laboratory, University College Cork, Cork, Ireland.en_GB
dc.identifier.journalCancer researchen_GB
dc.description.provinceMunster
html.description.abstractInfiltration of tumors by regulatory T cells confers growth and metastatic advantages by inhibiting antitumor immunity and by production of receptor activator of NF-kappaB (RANK) ligand, which may directly stimulate metastatic propagation of RANK-expressing cancer cells. Modulation of regulatory T cells can enhance the efficacy of cancer immunotherapy. Strategies include depletion, interference with function, inhibition of tumoral migration, and exploitation of T-cell plasticity. Problems with these strategies include a lack of specificity, resulting in depletion of antitumor effector T cells or global interruption of regulatory T cells, which may predispose to autoimmune diseases. Emerging technologies, such as RNA interference and tetramer-based targeting, may have the potential to improve selectivity and efficacy.


This item appears in the following Collection(s)

Show simple item record